SCHEMBL763446

SCHEMBL763446

CCN1CCN(CCc2c[nH]c3ccccc23)CC1

nearest known ligand 0.76

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.76
HTR1A P08908 5/20 0.71
HTR6 P50406 1/20 0.61
DRD2 P14416 5/20 0.61
DRD3 P35462 4/20 0.61
DRD1 P21728 2/20 0.61
DRD4 P21917 2/20 0.61
DRD5 P21918 2/20 0.61
BCHE P06276 1/20 0.60
CYP2D6 P10635 1/20 0.60
ABCB1 P08183 1/20 0.55
ABCC1 P33527 1/20 0.55
ABCG2 Q9UNQ0 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6465788 0.92 HTR2A (0.88) HTR2AHTR1AHTR6DRD2DRD3
SCHEMBL735143 0.90 HTR2A (0.78) HTR2AHTR1AHTR6DRD2DRD3
SCHEMBL20244861 0.87 HTR2A (0.78) HTR2AHTR1AHTR6DRD2DRD3
SCHEMBL25295661 0.86 HTR2A (1.00) HTR2AHTR1ADRD2DRD3DRD1
SCHEMBL29543272 0.86 HTR2A (0.94) HTR2AHTR1ADRD2DRD3DRD1
SCHEMBL733629 0.86 HTR2A (0.94) HTR2AHTR1ADRD2DRD3DRD1
SCHEMBL11679648 0.85 HTR2A (0.76) HTR2AHTR1AHTR6DRD2DRD3
SCHEMBL32669458 0.85 HTR2A (0.91) HTR2AHTR1ADRD2DRD3DRD1
SCHEMBL734226 0.85 HTR2A (0.91) HTR2AHTR1ADRD2DRD3DRD1
SCHEMBL24746493 0.85 HTR2A (0.70) HTR2AHTR1AHTR6DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138174-B2 Such as N-{1-[7-(2-amino-ethoxyimino)-7-[4-(trifluoromethyl)phenyl]heptylamino]-1-[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-methylidene)-4-chloro-benzenesulfonamide; pain. psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity; neurodegenerative disorders SOLVAY PHARMACEUTICALS B.V. (NL) 2012-03-20 US disclosed